Skyrizi gains new approval; the USPSTF makes recommendations on supplement use to prevent CVD and cancer; an FDA panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; new Phexxi data; and Vaxneuvance approved for pediatric use.